Latest news with #FormS-1
Business Wire
6 days ago
- Business
- Business Wire
Figure Technology Solutions, Inc. Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering
NEW YORK--(BUSINESS WIRE)--Figure Technology Solutions, Inc. ('FTS') today announced that it has confidentially submitted a draft registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the 'SEC'), relating to the proposed initial public offering of its equity securities expected in 2025. The number of shares to be offered and the price range for the proposed offering have not yet been determined. The offering is subject to market and other conditions, as well as the completion of the SEC's review process. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended ('Securities Act'). This announcement is being issued in accordance with Rule 135 under the Securities Act.
Business Upturn
01-08-2025
- Business
- Business Upturn
Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds
Cayman Islands, July 31, 2025 (GLOBE NEWSWIRE) — Silexion Therapeutics Corp. (NASDAQ: SLXN) ('Silexion Therapeutics' or the 'Company'), a clinical-stage biotech company developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 152,106 of the Company's ordinary shares originally issued in January 2025 at a reduced exercise price of $11.57 per share. The ordinary shares issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (File No. 333-282932) and an effective resale registration statement on Form S-1 (No. 333-284873). The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $1.8 million, prior to deducting placement agent fees and estimated offering expenses. The offering is expected to close on or about August 1, 2025, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering as working capital for general corporate purposes. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. In consideration for the immediate exercise of the warrants for cash, the Company will issue new unregistered warrants to purchase up to 304,212 of the Company's ordinary shares. The new warrants will have an exercise price of $11.32 per share, will be exercisable upon the effective date of the increase of the Company's authorized ordinary shares following shareholder approval and will have a term of twenty-four months from the effective date of the Resale Registration Statement (as defined below). The new warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the '1933 Act') and, along with the ordinary shares issuable upon their exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission ('SEC') or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC covering the resale of the ordinary shares issuable upon exercise of the new warrants (the 'Resale Registration Statement'). This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. About Silexion Therapeutics Silexion Therapeutics Corp is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations, the most common oncogenic driver in human cancers. The Company's first-generation product, LODER™, has shown promising results in a Phase 2 trial for non-resectable pancreatic cancer. Silexion is also advancing its next-generation siRNA candidate, SIL-204, designed to target a broader range of KRAS mutations and showing significant potential in preclinical studies. The company remains committed to pushing the boundaries of therapeutic innovation in oncology, with a focus on improving outcomes for patients with difficult-to-treat cancers. For more information please visit: Notice Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact contained in this communication, including statements regarding the completion of the offering, the satisfaction of customary closing conditions related to the offering and the intended use of net proceeds from the offering. These forward-looking statements are generally identified by terminology such as 'may', 'should', 'could', 'might', 'plan', 'possible', 'project', 'strive', 'budget', 'forecast', 'expect', 'intend', 'will', 'estimate', 'anticipate', 'believe', 'predict', 'potential' or 'continue', or the negatives of these terms or variations of them or similar terminology. For example, the Company is using forward-looking statements when it discusses the timing and completion of the offering, the satisfaction of customary closing conditions related to the offering and the intended use of proceeds therefrom. Forward-looking statements involve a number of risks, uncertainties, and assumptions, and actual results or events may differ materially from those projected or implied in those statements. Important factors that could cause such differences include, but are not limited to: (i) whether Silexion is able to successfully complete preclinical studies and initiate clinical trials; (ii) Silexion's strategy, future operations, financial position, projected costs, prospects, and plans; (iii) the impact of the regulatory environment and compliance complexities; (iv) expectations regarding future partnerships or other relationships with third parties; (v) Silexion's future capital requirements and sources and uses of cash, including its ability to obtain additional capital; and (vi) whether Silexion succeeds at maintaining the listing of its securities on the Nasdaq Capital Market. Silexion cautions you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information currently available as of the date a forward-looking statement is made. Forward-looking statements set forth herein speak only as of the date they are made. Silexion undertakes no obligation to revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs, except as otherwise required by law. Company Contact: Silexion Therapeutics CorpMs. Mirit Horenshtein Hadar, CFO [email protected]
Business Wire
25-07-2025
- Business
- Business Wire
Caliber Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering
LEWISVILLE, Texas--(BUSINESS WIRE)--Caliber Holdings Inc. ('Caliber') today announced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the 'SEC') relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. Caliber expects to use the proceeds from the offering for general corporate purposes, which may include the repayment of indebtedness. This news release is being made pursuant to and in accordance with Rule 135 under the Securities Act of 1933, as amended, and does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.
Business Wire
25-07-2025
- Business
- Business Wire
Accelerant Holdings Announces Closing of Upsized Initial Public Offering and Full Exercise of Over-Allotment Option
ATLANTA--(BUSINESS WIRE)--Accelerant Holdings ('Accelerant') announced today the closing of its upsized initial public offering of 39,630,324 of its Class A common shares, par value $0.0000011951862 per share (the 'Common Shares'), at a price to the public of $21.00 per Common Share. The offering consisted of 20,276,280 Common Shares offered by Accelerant and 19,354,044 Common Shares sold by certain of Accelerant's existing shareholders (the 'Selling Shareholders'), which includes 5,169,172 Common Shares sold pursuant to the full exercise by the underwriters of their over-allotment option. Accelerant will not receive any proceeds from the sale of Common Shares by the Selling Shareholders. The Common Shares began trading on the New York Stock Exchange under the ticker symbol 'ARX' on July 24, 2025. Morgan Stanley & Co. LLC acted as lead left active bookrunner, Goldman Sachs & Co. LLC acted as lead right active bookrunner, and BMO Capital Markets Corp. and RBC Capital Markets, LLC acted as active bookrunners for the offering. Wells Fargo Securities, LLC; Piper Sandler & Co.; William Blair & Company, L.L.C.; Raymond James & Associates, Inc.; and TD Securities (USA) LLC acted as bookrunners. Citizens Capital Markets and FT Partners acted as co-managers. The offering of Accelerant's Common Shares was made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained for free by visiting EDGAR on the U.S. Securities and Exchange Commission's (the 'SEC') website at Alternatively, copies of the final prospectus may be obtained from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014 or by email at prospectus@ Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526, or by email at prospectus-ny@ BMO Capital Markets Corp., Attention: Equity Syndicate Department, 151 W 42nd Street, 32nd Floor, New York, NY 10036, by telephone at (800) 414-3627, or by email at bmoprospectus@ RBC Capital Markets, LLC, Attention: Equity Capital Markets, 200 Vesey Street, 8th Floor, New York, NY 10281, by telephone at (877) 822-4089, or by email at equityprospectus@ A registration statement on Form S-1 relating to the Common Shares was declared effective by the SEC on July 23, 2025. This press release does not constitute an offer to sell or the solicitation of an offer to buy Common Shares, and shall not constitute an offer, solicitation or sale in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction. ABOUT ACCELERANT Accelerant is a data-driven risk exchange connecting underwriters of specialty insurance risk with risk capital providers. Accelerant was founded in 2018 by a group of longtime insurance industry executives and technology experts who shared a vision of rebuilding the way risk is exchanged – so that it works better, for everyone. The Accelerant risk exchange does business across 22 different countries and more than 500 specialty insurance products.
Yahoo
25-07-2025
- Business
- Yahoo
XRP Gets Its Own Treasury Company: Look Who's Building A $20 Million XRP Reserve
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Nature's Miracle Holding Inc. (OTCQB:NMHI), a publicly listed vertical farming technology firm, on Wednesday announced plans to allocate up to $20 million towards a new corporate treasury strategy centered around Ripple's (CRYPTO: XRP). The company stated that it will use proceeds from a recently approved equity financing arrangement to fund the purchase of XRP tokens, with aims to treat the cryptocurrency as a long-term strategic reserve. The decision makes Nature's Miracle one of the first publicly traded non-financial companies to adopt XRP, currently the third-largest cryptocurrency by market capitalization, as a treasury asset. Don't Miss: 7,000+ investors have joined Timeplast's mission to eliminate microplastics— This AI-Powered Trading Platform Has 5,000+ Users, 27 Pending Patents, and a $43.97M Valuation — You Can Become an Investor for Just $500.25 The company also plans to engage with staking opportunities and broader participation in the Ripple ecosystem. According to the release, the funding will initially come from capital raised under a registration statement on Form S-1 declared effective by the U.S. Securities and Exchange Commission. Further XRP purchases may be financed through a mix of equity issuances, structured financing, and strategic placements. CEO James Li attributed the move to increased regulatory clarity following the recent passage of the GENIUS Act, signed into law by President Donald Trump on July 18, which has encouraged broader corporate participation in the digital asset space. 'We see the huge potential of XRP as it improves the speed and reduces the cost of cross-border payments,' Li said. Nature's Miracle joins a growing list of companies engaged with XRP. Financial institutions such as Banco Santander (NYSE:SAN) and American Express (NYSE:AXP) have already incorporated Ripple's payment technologies into their operations. In 2023, Japan's SBI Holdings announced the use of XRP in its internal treasury operations, while other blockchain-native firms have used XRP for cross-border liquidity and remittance flows. Read Next: $100k+ in investable assets? Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes – no cost, no obligation. If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends would you invest in it? Image: Shutterstock This article XRP Gets Its Own Treasury Company: Look Who's Building A $20 Million XRP Reserve originally appeared on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
